Rosuvastatin Zinc to be Released Into Market
Posted: Mar 28 2016

FDA Drug Approvals

Each month the FDA approves new medications, and below is a highlight of the most relevant new approvals and/or drugs which have the potential to impact your prescription plan. While the medications below have been evaluated and approved by the FDA, they may not enter the marketplace for several weeks or months. Therefore, pricing information for these medications is typically unavailable at the time of approval.   

 

New Brand Approvals
Drug NameUses/TreatmentPricing InformationAdditional Information
Sernivo™ (betamethasone dipropionate topical spray)Treatment of mild to moderate plaque psoriasisPricing information not yet available• Drug Information: Topical (applied to skin) formulation of betamethasone, a highly potent corticosteroid.  Sernivo is not indicated for long-term use.
• Formulary Management: Considered non-preferred upon market entry. 
• Control Trak: Subject to max dollar and max dose edits.
Briviact® (brivaracetam)Adjunctive therapy in the treatment of partial-onset seizuresPricing information not yet available• Drug Information: Briviact will be available in multiple formulations including oral tablets, oral solution, and injection for IV use.  It is approved for use in patients 16 years of age and older and is intended to be used in conjunction with other anti-epileptic drug therapies.
• Formulary Management: Considered non-preferred upon market entry. 
• Control Trak: Subject to max dollar and max dose edits.
Rosuvastatin zincTreatment of various dyslipidemias (elevated cholesterol, triglycerides, or both)Pricing information not yet available• Drug Information: New salt form of rosuvastatin.  Although rosuvastatin calcium is the active ingredient in Crestor®, this product is not considered a generic equivalent.  Rosuvastatin zinc was approved by the FDA under a new drug application (NDA) and is considered a brand name drug product.  
• Formulary Management: Considered non-preferred upon market entry. 
• Clinical Concierge: Rosuvastatin zinc will be added to MedTrak’s lipid-lowering (high cholesterol) step therapy program as a step-two medication.
Control Trak: Subject to max dollar and max dose edits.

The Clinical Care Center (CCC) is MedTrak’s comprehensive clinical solution to control costs and increase adherence for our Clients and Members. The Clinical Care Center is made up of 7 Steps to Improved Outcomes: Generics Plus, Formulary Management, Member & Client Education, RightChoice, Control Trak, Best-In-Class (BIC) SpecialtyRx, and Clinical Concierge.